论文部分内容阅读
目的制备188Re标记丙氧鸟苷(GCV)白蛋白纳米微球(188Re-GCV-BSA-NP)。方法通过蛋白交联固化的方法制备GCV-BSA-NP,并测定GCV-BSA-NP的体外释药特性;采用预锡化直接标记法对GCV-BSA-NP进行188Re标记,同时观察188Re-GCV-BSA-NP体外稳定性。结果GCV-BSA-NP为大小不等的规则性微球,微球直径不等,但多集中在250~290nm。GCV-BSA-NP总的标记率>90%,放化纯>95%,放射性比活度1.85×105MBq/μmol。标记物放置于37℃的PBS(pH7.4)溶液中,在24h时放化纯为95%。结论预锡化直接标记法简便快速,能够得到较高的标记物放化纯度,稳定性好,GCV-BSA-NP具有明显的缓释功能。
Objective To prepare 188Re-labeled guanosine glycoside (GCV) albumin nanospheres (188Re-GCV-BSA-NP). Methods The GCV-BSA-NP was prepared by protein cross-linking and solidification. The in vitro release characteristics of GCV-BSA-NP were determined. The 188Re-labeled GCV-BSA-NP was labeled by direct tin- -BSA-NP in vitro stability. Results GCV-BSA-NPs were regular microspheres with different sizes. The diameter of microspheres varied from 250 nm to 290 nm. The total labeling rate of GCV-BSA-NP> 90%, radiochemical purity> 95%, radioactive specific activity 1.85 × 105MBq / μmol. The label was placed in a solution of PBS (pH 7.4) at 37 ° C and pure at 95% for 24 h. Conclusion The direct pre-tin labeling method is simple, rapid, high radiochemical purity and good stability of GCV-BSA-NP.